The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Sanofi Pharmaceuticals
Approval Status: Approved March 1998
Treatment for: acute bacterial exacerbations
General Information
Dynabac, a member of the newer macrolide group of antibiotics, has received approval for expanded coverage within certain indications, including the treatment of acute bacterial exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections. Dynabac remains a once-a-day therapy.
Side Effects
The most common side effects were gastrointestinal, including abdominal pain, nausea, and diarrhea.
